Table 1 The relationship between the percentage of PD-1/PD-L1 positive circulating T lymphocytes and clinicopathological characters

Age^a

  ≤ 50

25

14.40(8.30–37.90)

0.80(0.20–3.40)

  > 50

52

15.25(3.60–41.20)

0.70(0–6.50)

Tumor size^b

 T1

43

16.50(3.60–39.70)

0.90(0.20–6.50)

 T2

30

12.80(8.80–41.20)

0.70(0–3.40)

 T3

4

12.10(8.60–14.60)

0.55(0.40–1.10)

Lymph node metastasis^a

 Yes

21

15.20(3.60–39.70)

1.40(0.30–3.50)

 No

55

14.60(6.80–41.20)

0.60(0–3.40)

cTNM stage^b

 I

37

16.50(8.20–39.70)

0.60(0.20–6.50)

 II

24

17.15(3.60–41.20)

0.90(0–3.40)

 III

16

11.20(8.60–19.80)

0.55(0.10–2.50)

Histological grade^b

 I

6

14.20(12.80–18.50)

1.15(0.10–3.20)

 II

43

16.30(3.60–28.10)

0.70(0.20–3.40)

 III

8

25.40(8.30–41.20)

1.30(0.40–3.50)

ER^a

 Positive

54

15.25(3.60–37.90)

0.70(0.10–3.40)

 Negative

22

15.55(8.30–41.20)

0.70(0–6.50)

PR^a

 Positive

50

15.25(3.60–41.20)

0.65(0.10–3.40)

 Negative

26

15.55(8.30–39.70)

0.75(0–6.50)

HER-2^a

 Positive

15

12.90(8.30–30.10)

0.50(0–3.20)

 Negative

58

15.55(3.60–41.20)

0.90(0.10–3.50)

Ki-67 index^a

 Low(≤ 14%)

22

15.10(8.20–28.10)

0.45(0.10–2.90)

 High (> 14%)

53

14.60(3.60–41.20)

0.70(0.20–6.50)

Molecular subtype^c

 Luminal A

18

14.25(8.20–26.00)

0.70(0.10–2.90)

 Luminal B

36

16.50(3.60–37.90)

1.10(0.20–3.40)

 TNBC

13

20.79(8.60–41.20)

1.45(0.40–3.50)

 HER-2 overexpression

8

11.05(8.30–28.10)

0.40(0–6.50)